313 related articles for article (PubMed ID: 20833335)
1. Endocrine tumours in neurofibromatosis type 1, tuberous sclerosis and related syndromes.
Lodish MB; Stratakis CA
Best Pract Res Clin Endocrinol Metab; 2010 Jun; 24(3):439-49. PubMed ID: 20833335
[TBL] [Abstract][Full Text] [Related]
2. Endocrine tumors associated with neurofibromatosis type 1, Peutz-Jeghers syndrome and other familial neoplasia syndromes.
Kalkan E; Waguespack SG
Front Horm Res; 2013; 41():166-81. PubMed ID: 23652677
[TBL] [Abstract][Full Text] [Related]
3. Molecular therapies for tuberous sclerosis and neurofibromatosis.
Franz DN; Weiss BD
Curr Neurol Neurosci Rep; 2012 Jun; 12(3):294-301. PubMed ID: 22544507
[TBL] [Abstract][Full Text] [Related]
4. Phakomatoses and Endocrine Gland Tumors: Noteworthy and (Not so) Rare Associations.
Chevalier B; Dupuis H; Jannin A; Lemaitre M; Do Cao C; Cardot-Bauters C; Espiard S; Vantyghem MC
Front Endocrinol (Lausanne); 2021; 12():678869. PubMed ID: 34025587
[TBL] [Abstract][Full Text] [Related]
5. Lessons from the skin--cutaneous features of familial cancer.
Winship IM; Dudding TE
Lancet Oncol; 2008 May; 9(5):462-72. PubMed ID: 18452857
[TBL] [Abstract][Full Text] [Related]
6. Phakomatoses.
Becker B; Strowd RE
Dermatol Clin; 2019 Oct; 37(4):583-606. PubMed ID: 31466597
[TBL] [Abstract][Full Text] [Related]
7. The genetics and diagnosis of pediatric neurocutaneous disorders: Neurofibromatosis and tuberous sclerosis complex.
Tolliver S; Smith ZI; Silverberg N
Clin Dermatol; 2022; 40(4):374-382. PubMed ID: 35248688
[TBL] [Abstract][Full Text] [Related]
8. Mourning Dr. Alfred G. Knudson: the two-hit hypothesis, tumor suppressor genes, and the tuberous sclerosis complex.
Hino O; Kobayashi T
Cancer Sci; 2017 Jan; 108(1):5-11. PubMed ID: 27862655
[TBL] [Abstract][Full Text] [Related]
9. Differentiating the mTOR inhibitors everolimus and sirolimus in the treatment of tuberous sclerosis complex.
MacKeigan JP; Krueger DA
Neuro Oncol; 2015 Dec; 17(12):1550-9. PubMed ID: 26289591
[TBL] [Abstract][Full Text] [Related]
10. mTOR inhibitors in the pharmacologic management of tuberous sclerosis complex and their potential role in other rare neurodevelopmental disorders.
Franz DN; Capal JK
Orphanet J Rare Dis; 2017 Mar; 12(1):51. PubMed ID: 28288694
[TBL] [Abstract][Full Text] [Related]
11. The tuberous sclerosis complex genes in tumor development.
Mak BC; Yeung RS
Cancer Invest; 2004; 22(4):588-603. PubMed ID: 15565817
[TBL] [Abstract][Full Text] [Related]
12. Tuberous sclerosis--A model for tumour growth.
Dodd KM; Dunlop EA
Semin Cell Dev Biol; 2016 Apr; 52():3-11. PubMed ID: 26816112
[TBL] [Abstract][Full Text] [Related]
13. Dysregulation of the TSC-mTOR pathway in human disease.
Inoki K; Corradetti MN; Guan KL
Nat Genet; 2005 Jan; 37(1):19-24. PubMed ID: 15624019
[TBL] [Abstract][Full Text] [Related]
14. Update on the management of familial central nervous system tumor syndromes.
Hottinger AF; Khakoo Y
Curr Neurol Neurosci Rep; 2007 May; 7(3):200-7. PubMed ID: 17488585
[TBL] [Abstract][Full Text] [Related]
15. [Genetics of neuroendocrine tumours, hereditary tumour syndromes].
Igaz P
Orv Hetil; 2013 Sep; 154(39):1541-8. PubMed ID: 24058099
[TBL] [Abstract][Full Text] [Related]
16. Neurocutaneous syndromes: neurofibromatosis 1, neurofibromatosis 2, and tuberous sclerosis.
Korf BR
Curr Opin Neurol; 1997 Apr; 10(2):131-6. PubMed ID: 9146993
[TBL] [Abstract][Full Text] [Related]
17. Topical Use of Mammalian Target of Rapamycin (mTOR) Inhibitors in Tuberous Sclerosis Complex-A Comprehensive Review of the Literature.
Jóźwiak S; Sadowski K; Kotulska K; Schwartz RA
Pediatr Neurol; 2016 Aug; 61():21-7. PubMed ID: 27222056
[TBL] [Abstract][Full Text] [Related]
18. Proteomic analysis reveals hyperactivation of the mammalian target of rapamycin pathway in neurofibromatosis 1-associated human and mouse brain tumors.
Dasgupta B; Yi Y; Chen DY; Weber JD; Gutmann DH
Cancer Res; 2005 Apr; 65(7):2755-60. PubMed ID: 15805275
[TBL] [Abstract][Full Text] [Related]
19. Deficient TSC1/TSC2-complex suppression of SOX9-osteopontin-AKT signalling cascade constrains tumour growth in tuberous sclerosis complex.
Jin F; Jiang K; Ji S; Wang L; Ni Z; Huang F; Li C; Chen R; Zhang H; Hu Z; Zha X
Hum Mol Genet; 2017 Jan; 26(2):407-419. PubMed ID: 28013293
[TBL] [Abstract][Full Text] [Related]
20. Genetic Etiologies, Diagnosis, and Treatment of Tuberous Sclerosis Complex.
Salussolia CL; Klonowska K; Kwiatkowski DJ; Sahin M
Annu Rev Genomics Hum Genet; 2019 Aug; 20():217-240. PubMed ID: 31018109
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
